These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 35241483

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 43. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
    Rahman LA, Rutagengwa D, Lin P, Lin M, Yap J, Lai K, Mancuso P, Rathore P, Haghighi K, Gassner P, Wong LH, Lalak N.
    Cancer Imaging; 2019 Dec 11; 19(1):86. PubMed ID: 31829288
    [Abstract] [Full Text] [Related]

  • 44. Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
    Meijer D, Donswijk ML, Bodar YJL, van Leeuwen PJ, Poel HGV, Vogel WV, Nieuwenhuijzen JA, Hendrikse NH, Oprea-Lager DE, Vis AN.
    J Nucl Med; 2021 Jul 01; 62(7):961-967. PubMed ID: 33158904
    [Abstract] [Full Text] [Related]

  • 45. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT.
    Theranostics; 2017 Jul 01; 7(6):1770-1780. PubMed ID: 28529650
    [Abstract] [Full Text] [Related]

  • 46. Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases.
    Lunger L, Steinhelfer L, Korn P, Eiber M, Maurer T, Büchler J, Horn T, Gschwend JE, Heck MM.
    Eur Urol Oncol; 2023 Feb 01; 6(1):95-98. PubMed ID: 36604297
    [Abstract] [Full Text] [Related]

  • 47. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb 01; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 48. Prostate-Specific Membrane Antigen Radioguided Surgery for Salvage Pelvic Lymph Node Dissection in a Man With Prostate Cancer.
    Erfani S, Sadeghi R, Aghaee A, Ghorbani H, Roshanravan V.
    Clin Nucl Med; 2022 Feb 01; 47(2):e174-e176. PubMed ID: 34690293
    [Abstract] [Full Text] [Related]

  • 49. A DROP-IN beta probe for robot-assisted 68Ga-PSMA radioguided surgery: first ex vivo technology evaluation using prostate cancer specimens.
    Collamati F, van Oosterom MN, De Simoni M, Faccini R, Fischetti M, Mancini Terracciano C, Mirabelli R, Moretti R, Heuvel JO, Solfaroli Camillocci E, van Beurden F, van der Poel HG, Valdes Olmos RA, van Leeuwen PJ, van Leeuwen FWB, Morganti S.
    EJNMMI Res; 2020 Aug 06; 10(1):92. PubMed ID: 32761408
    [Abstract] [Full Text] [Related]

  • 50. [99mTc]Tc-HYNIC-ALUG SPECT/CT in the initial staging of 227 consecutive patients with newly diagnosed prostate cancer: a 5-year monocentric retrospective study.
    Li B, Ding X, Duan L, Shi J, Tang M, Zhang J, Zhao Z, Wu X, Gao Y.
    Front Endocrinol (Lausanne); 2024 Aug 06; 15():1326858. PubMed ID: 38449842
    [Abstract] [Full Text] [Related]

  • 51. Multimodal hybrid imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot-assisted surgery.
    KleinJan GH, van den Berg NS, de Jong J, Wit EM, Thygessen H, Vegt E, van der Poel HG, van Leeuwen FW.
    Eur J Nucl Med Mol Imaging; 2016 Jul 06; 43(7):1278-87. PubMed ID: 26768422
    [Abstract] [Full Text] [Related]

  • 52. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D.
    J Urol; 2019 Apr 06; 201(4):815-820. PubMed ID: 30672842
    [Abstract] [Full Text] [Related]

  • 53. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb 06; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

  • 54. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
    BJU Int; 2017 Feb 06; 119(2):209-215. PubMed ID: 27207581
    [Abstract] [Full Text] [Related]

  • 55. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.
    Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.
    J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970
    [Abstract] [Full Text] [Related]

  • 56. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
    Duncan I, Ingold N, Martinez-Marroquin E, Paterson C.
    Prostate; 2023 Jul 07; 83(10):970-979. PubMed ID: 37051636
    [Abstract] [Full Text] [Related]

  • 57. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
    Du X, Dong Y, Liu J, Su Y, Zhu Y, Pan J, Dong B, Chen R, Liu J, Tong Z, Pienta KJ, Rowe SP, Dong L, Xue W.
    Prostate; 2023 Aug 07; 83(11):1112-1120. PubMed ID: 37165552
    [Abstract] [Full Text] [Related]

  • 58. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.
    Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M.
    Eur J Nucl Med Mol Imaging; 2019 Sep 07; 46(10):2169-2177. PubMed ID: 31254037
    [Abstract] [Full Text] [Related]

  • 59. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T, Gschwend JE, Eiber M.
    Curr Opin Urol; 2018 Mar 07; 28(2):191-196. PubMed ID: 29028767
    [Abstract] [Full Text] [Related]

  • 60. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.
    Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.
    Prostate; 2015 Dec 07; 75(16):1934-40. PubMed ID: 26356236
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.